Biomarker finding of individual salviol B exposures in healthy subjects

Abstract

Abstract: AIM: To set a linear regression model in selecting 1-4 point blood concentrations as biomarkers for predicting AUC_{0-24 h} and Cmax in individual therapy.METHODS: The blood concentrations of salviol B were determined by HPLC-UA and the data within 7 h were used to set model. The reliability and stability of the model was evaluated with the absolute prediction error (APE) by Jackknife method and plotting.RESULTS: A limited sampling model was set with 1-4 point concentrations by the regression model with plotting. One point for prediction of AUC_{0-24 h} showed 15% APE 29.6% in subjects, but two, three or four points could obtain better prediction with less than 15% APE in all subjects. There were the same results in the prediction of C_max in the subjects.CONCLUSION: Two-four point blood concentrations of salviol B can be taken as biomarkers to predict the AUC_{0-24 h} and C_max for individual therapy.

Key words: Salviol B, Modeling, Limited sampling model, Jackknife, Biomarker

CLC Number:

R969.1

HUANG Ji-han, WANG Kun, XU Ling, HE Ying-chun, LI Lu-jin, YANG Juan, SHENG Yu-cheng, ZHENG Qing-shan. Biomarker finding of individual salviol B exposures in healthy subjects[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(5): 510-516.

References

[1] Johnston A, Sketris I, Marsden JT, et al. A limited sampling strategy for the measurement of cyclosporine AUC[J]. Transplant Proc, 1990, 22(3): 1345-1346.
[2] Suarez-Kurtz G, Vicente FL, Ponte CG, et al. Limited-sampling strategy models for estimating the area under the plasma concentration-time curve for amlodipine[J]. Eur J Clin Pharmacol, 1999, 55(9): 651-657.
[3] Monchaud C, Rousseau A, Leger F, et al. Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC_(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation[J]. Eur J Clin Pharmacol, 2003, 58(12): 813-820.
[4] Zicheng Y, Peijun Z, Da X, et al. Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients[J]. Br J Clin Pharmacol, 2006, 62(4): 446-452.
[5] Bolon-Larger M, Chamouard V, Bressolle F, et al. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A[J]. Ther Drug Monit, 2007, 29(1): 20-26.
[6] Dickinson L, Back D, Pozniak A, et al. Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals[J]. Ther Drug Monit, 2007, 29(3): 361-367.
[7] Jiao Z, Zhong JY, Zhang M, et al. Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies[J]. Eur J Clin Pharmacol, 2007, 63(1): 27-37.
[8] 高蕊,张颖,王书臣,等. 丹参酚酸盐在健康志愿者的药代动力学和药效学研究[J]. 中国临床药理学与治疗学, 2004, 9(11): 1209-1212.
[9] Quenouille M. Approximate tests of correlation in time series[J]. J R Stat Soc Series B Stat Methodol, Series B, 1949, 11(1):68-84.
[10] Quenouille M. Notes on bias in estimation[J]. Biometrika, 1956, 61:353-360.
[11] Efron B. Bootstrap Methods: Another Look at the Jackknife[J]. Annals of Statistics, 1979, 7(1):1-12.
[12] Dupuis LL, Sibbald C, Schechter T, et al. IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies[J]. Biol Blood Marrow Transplant, 2008, 149(5): 576-582.

[1]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[2]	FU Xiaoyu, KONG Deguang, LI Juanjuan. Treatment progress of triple positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
[3]	XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua. Research progress of biomarkers related to the efficacy of HER2 positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
[4]	HAO Xiao, ZHAO Mei, WANG Wenjing, ZHANG Feifei, LIU Huiliang, DANG Yi, LI Shuren, QI Xiaoyong. Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 824-831.
[5]	HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle. Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
[6]	DING Hao, GAO Zhenhua, ZHENG Yun. Research progress of microRNA in diagnosis and treatment of prostate cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 696-708.
[7]	ZHOU Guangchen, LIU Yixi, ZHENG Yun. Colorectal cancer and microRNA: research progress [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 575-587.
[8]	PENG Juan, LI Ranyi, FAN Linlin, LI Xiaoyu, LV Qianzhou, ZOU Yunzeng. Progress of pharmacotherapy for myocardial hypertrophy and cardiac remodeling [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 382-389.
[9]	ZHANG Jinhua, LIU Maobai, CAI Mingzhi, ZHENG Yingli, LAO Haiyan, XIANG Qian, DU Liping, ZHU Zhu, DONG Jing, ZUO Xiaocong, LI Xingang, SHANG Dewei, CHEN Bing, YE Yanrong, WANG Yuzhu, GAO Jianjun, ZHANG Jian, CHEN Wansheng, XIE Haitang, JIAO Zheng. Model informed precision dosing of warfarin: China expert consensus report (2022 version) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1201-1212.
[10]	XU Yonghua, SHI Xianghong. Analysis of the efficacy of torasemide combined with levocarnitine in the treatment of chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 647-652.
[11]	ZHANG Ningyuan, ZHENG Xijun, XU Ling, LIU Hongxia, ZHENG Qingshan. Disease progression model for Alzheimer's disease and its research progress [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 687-694.
[12]	WU Dan, DIAO Yong, XU Xianxiang. Progress in research on hyperuricemia cell model [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 236-240.
[13]	JIAO Zheng, LI Xingang, SHANG Dewei, DONG Jing, ZUO Xiaocong, CHEN Bing, LIU Jianmin, PAN Yan, ZHOU Tianyan, ZHANG Jing, LIU Dongyang, LI Lujin, FANG Yi, MA Guangli, DING Junjie, ZHAO Wei, CHEN Rui, XIANG Xiaoqiang, WANG Yuzhu, GAO Jianjun, XIE Haitang, HU Pei, ZHENG Qingshan. Model informed precision dosing: China expert consensus report [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1215-1228.
[14]	LU Chenyu, YANG Jun, LIU Yixi, ZHENG Yun. Function and regulation of miRNAs associated with Parkinson's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 775-783.
[15]	LI Jian, YANG Jinbo, WANG Yuzhu. Discussion on the format and content of new drug population pharmacokinetic study report [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 546-549.